508 related articles for article (PubMed ID: 29792136)
1. SGLT-2 inhibitors in Diabetic Kidney Disease: What Lies Behind their Renoprotective Properties?
Georgianos PI; Divani M; Eleftheriadis T; Mertens PR; Liakopoulos V
Curr Med Chem; 2019; 26(29):5564-5578. PubMed ID: 29792136
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms for Cardiorenal Protection of SGLT-2 Inhibitors.
Georgianos PI; Vaios V; Dounousi E; Salmas M; Eleftheriadis T; Liakopoulos V
Curr Pharm Des; 2021; 27(8):1043-1050. PubMed ID: 33463454
[TBL] [Abstract][Full Text] [Related]
3. [The mechanisms and clinical potential: sodium-glucose cotransporter 2 (SGLT-2) inhibitors treating diabetic kidney disease].
Wang YJ; Hao CM
Sheng Li Xue Bao; 2018 Dec; 70(6):663-669. PubMed ID: 30560277
[TBL] [Abstract][Full Text] [Related]
4. New Diabetes Therapies and Diabetic Kidney Disease Progression: the Role of SGLT-2 Inhibitors.
Dekkers CCJ; Gansevoort RT; Heerspink HJL
Curr Diab Rep; 2018 Mar; 18(5):27. PubMed ID: 29589183
[TBL] [Abstract][Full Text] [Related]
5. Renal effects of sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes and renal impairment.
Weir MR
Postgrad Med; 2019 Aug; 131(6):367-375. PubMed ID: 31132013
[TBL] [Abstract][Full Text] [Related]
6. Sodium-glucose Cotransporter 2 Inhibitors: Nephroprotective Impact on Diabetic Kidney Disease.
Stavropoulos K; Imprialos KP; Stavropoulos N; Bouloukou S; Kerpiniotis G; Dimitriadis K; Tsioufis C; Doumas M
Cardiovasc Hematol Disord Drug Targets; 2018; 18(2):120-126. PubMed ID: 29412122
[TBL] [Abstract][Full Text] [Related]
7. SGLT2 Inhibitors as a Therapeutic Option for Diabetic Nephropathy.
Kawanami D; Matoba K; Takeda Y; Nagai Y; Akamine T; Yokota T; Sango K; Utsunomiya K
Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28524098
[TBL] [Abstract][Full Text] [Related]
8. Sodium-Glucose Cotransporter 2 Inhibition and Diabetic Kidney Disease.
Alicic RZ; Neumiller JJ; Johnson EJ; Dieter B; Tuttle KR
Diabetes; 2019 Feb; 68(2):248-257. PubMed ID: 30665953
[TBL] [Abstract][Full Text] [Related]
9. Role and mechanisms of SGLT-2 inhibitors in the treatment of diabetic kidney disease.
Dai ZC; Chen JX; Zou R; Liang XB; Tang JX; Yao CW
Front Immunol; 2023; 14():1213473. PubMed ID: 37809091
[TBL] [Abstract][Full Text] [Related]
10. Sodium glucose cotransporter (SGLT)-2 inhibitors: Do we need them for glucose-lowering, for cardiorenal protection or both?
Scholtes RA; van Baar MJB; Lytvyn Y; Bjornstad P; Nieuwdorp M; Cherney DZI; van Raalte DH
Diabetes Obes Metab; 2019 Apr; 21 Suppl 2(Suppl 2):24-33. PubMed ID: 30843294
[TBL] [Abstract][Full Text] [Related]
11. SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease.
Zou H; Zhou B; Xu G
Cardiovasc Diabetol; 2017 May; 16(1):65. PubMed ID: 28511711
[TBL] [Abstract][Full Text] [Related]
12. The effect of SGLT-2 inhibitors on albuminuria and proteinuria in diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials.
Piperidou A; Sarafidis P; Boutou A; Thomopoulos C; Loutradis C; Alexandrou ME; Tsapas A; Karagiannis A
J Hypertens; 2019 Jul; 37(7):1334-1343. PubMed ID: 31145707
[TBL] [Abstract][Full Text] [Related]
13. SGLT-2 Inhibition: A Potential New Treatment for Diabetic Kidney Disease?
Toto RD
Nephron; 2017; 137(1):64-67. PubMed ID: 28743130
[TBL] [Abstract][Full Text] [Related]
14. Renoprotective effects of sodium-glucose cotransporter-2 inhibitors.
Heerspink HJL; Kosiborod M; Inzucchi SE; Cherney DZI
Kidney Int; 2018 Jul; 94(1):26-39. PubMed ID: 29735306
[TBL] [Abstract][Full Text] [Related]
15. Use of sodium-glucose co-transporter-2 inhibitors in Asian patients with type 2 diabetes and kidney disease: An Asian perspective and expert recommendations.
Khoo CM; Deerochanawong C; Chan SP; Matawaran B; Sheu WH; Chan J; Mithal A; Luk A; Suastika K; Yoon KH; Ji L; Man NH; Pollock C
Diabetes Obes Metab; 2021 Feb; 23(2):299-317. PubMed ID: 33155749
[TBL] [Abstract][Full Text] [Related]
16. Renal Benefits of SGLT 2 Inhibitors and GLP-1 Receptor Agonists: Evidence Supporting a Paradigm Shift in the Medical Management of Type 2 Diabetes.
Ninčević V; Omanović Kolarić T; Roguljić H; Kizivat T; Smolić M; Bilić Ćurčić I
Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31757028
[TBL] [Abstract][Full Text] [Related]
17. The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure.
Thomas MC; Cherney DZI
Diabetologia; 2018 Oct; 61(10):2098-2107. PubMed ID: 30132034
[TBL] [Abstract][Full Text] [Related]
18. SGLT2 Inhibition for the Prevention and Treatment of Diabetic Kidney Disease: A Review.
Alicic RZ; Johnson EJ; Tuttle KR
Am J Kidney Dis; 2018 Aug; 72(2):267-277. PubMed ID: 29866460
[TBL] [Abstract][Full Text] [Related]
19. Beat it early: putative renoprotective haemodynamic effects of oral hypoglycaemic agents.
Gnudi L; Karalliedde J
Nephrol Dial Transplant; 2016 Jul; 31(7):1036-43. PubMed ID: 25858586
[TBL] [Abstract][Full Text] [Related]
20. Renal protection by sodium-glucose cotransporter 2 inhibitors and its underlying mechanisms in diabetic kidney disease.
Mima A
J Diabetes Complications; 2018 Jul; 32(7):720-725. PubMed ID: 29880432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
